ARV drugs, treatment regimens (drug combinations) and formulations for children have remained limited especially for use in resource constrained settings in spite of increasing availability for adult therapy. A few drugs have been approved for use by the FDA in the USA, but based on research data that did not include "resource-limited" settings. There is still a gap in ART coverage in children that resides largely in these constrained settings, which could constitute a serious challenge in the effort to attain not just country/regional, but global targets as well.
Any evidence from available literature or clinical experience?
Dear Doc,
good daring to try to revise current WHO ART guideline for children,
my opinion is if there is no evidence at present! try to create evidence based on your clinical experience.
I totally agree that in recourse constrained setting there are limitations. So your point is valid,
however we always focus on potential benefit Vs Risk,...
so we can develop evidence only with clinical experience.
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology
- Medical Pharmacology
- Clinical Pharmacology